NasdaqGM:URGNBiotechs
A Look At UroGen Pharma (URGN) Valuation After New UGN-103 And ZUSDURI Bladder Cancer Data
UroGen Pharma (URGN) is back in focus after fresh Phase 3 data for UGN-103 in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer showed a 94.5% six-month durability of response, closely mirroring prior ZUSDURI results.
See our latest analysis for UroGen Pharma.
The latest UGN-103 and ZUSDURI data have arrived after a powerful run, with UroGen’s share price delivering a 90 day return of 43.18% and a one year total shareholder return of roughly 3x. The stock has eased...